15 results about "Pulmonary Macrophages" patented technology

The application discloses a compound containing a 3-alkynyl pyrrole structure and application thereof. The compound containing the 3-alkynyl pyrrole structure provided by the application is confirmed to have a down-regulation effect on inflammatory factors secreted by LPS-induced primary alveolar macrophages through cell experiments, and has no obvious cytotoxicity. The application provides a new treatment strategy for clinical acute lung injury (ALI) treatment.

Disclosed are Schistosoma japonicum eggs and the ingredients of secretions and excretions thereof, comprising eggs, egg culture supernatant, and egg secreted proteins. (hereinafter referred to as “Schistosoma eggs and secretions and excretions thereof” for short). A Schistosoma infection can significantly inhibit metastatic tumors of organs such as lungs, and an anti-tumor effect is mediated by the “Schistosoma eggs and secretions and excretions thereof”, which have the effect of inhibiting various host tumors, comprising lung cancer, liver cancer, melanoma, and hematological tumors. Two egg secreted proteins having an anti-tumor effect are further identified. The “Schistosoma eggs and secretions and excretions thereof” exert an anti-tumor effect by activating natural immunity such as alveolar macrophages. The “Schistosoma eggs and secretions and excretions thereof” have a potential application value in prevention and treatment of tumors in humans.

The invention provides a monoclonal antibody for detecting pig source CD163 protein and a corresponding antigen epitope peptide. Wherein the hybridoma cell strain used for preparing the monoclonal antibody is CCTCC (China Center For Type Culture Collection) NO: C2025258. The monoclonal antibody provided by the invention is good in specificity, has good affinity with pCD163, and is clear in epitope information. The antibody can significantly inhibit the infection efficiency of PRRSV pedigree strains in alveolar macrophages, has a good PRRSV in-vitro blocking effect, can be used for developing a high-specificity pCD163 detection reagent, and is expected to be used as a candidate drug for passive immune prevention and treatment of PRRS.

The invention discloses application of an SLC39A1 specific regulating agent in preparation of a medicine for treating acute respiratory distress syndrome, and relates to the technical field of biological medicine. The medicine comprises an SLC39A1 specific regulating agent with a therapeutically effective amount and a pharmaceutically acceptable lung directional delivery carrier, the SLC39A1 specific regulating agent is selected from a group consisting of a nucleic acid molecule capable of specifically up-regulating the expression of an SLC39A1 gene, a small molecule compound capable of enhancing the zinc transport activity of the SLC39A1 protein and a recombinant protein; the lung directional delivery carrier is configured to deliver the SLC39A1 specific regulating agent to alveolar macrophages or lung microvascular endothelial cells in a targeted manner.

The present invention relates to a composition for use in the treatment of pulmonary fibrosis of a subject, wherein the composition comprises an inhibitor of miR-21 and a moiety that delivers said inhibitor of miR-21 to a macrophage. Further, the composition may be administered by a pulmonary administration. In particular aspects, said subject to be treated suffers from pulmonary fibrosis and further has a lung disease or disorder, wherein the lung disease or disorder may be a corona virus disease. Furthermore, the invention relates to a composition, wherein the composition comprises an inhibitor of miR-21 and a moiety that delivers said inhibitor of miR-21 to a lung macrophage.

The invention belongs to the technical field of medicine. The invention discloses an application of forsythiaside A in preparation of a medicine for treating bacterial infectious pneumonia. The method comprises the following steps: firstly, establishing a model of mice bacterial infectious pneumonia caused by tracheal intubation instillation of Pseudomonas aeruginosa in vivo, and applying forsythiaside A to treat, so that the infection symptom of the model mice can be obviously relieved, and the lung inflammatory response can be effectively relieved. The method comprises the following steps: firstly, establishing a model of pulmonary alveolar macrophages infected with Pseudomonas aeruginosa, Klebsiella pneumoniae or Acinetobacter baumannii in vitro, and then, establishing a model of pulmonary alveolar macrophages infected with Pseudomonas aeruginosa, Klebsiella pneumoniae or Acinetobacter baumannii in vitro, so that after forsythiaside A is added, the damage of the macrophages can be effectively alleviated, and the number of infectious bacteria in cytoplasm can be reduced. Experimental results show that forsythiaside A can be effectively used for treating bacterial infectious pneumonia.

A method for generating progeny of an African swine fever (ASF) virus includes providing an isolated or purified fetal porcine lung alveolar macrophage cell capable of replicating the ASF virus, wherein the cell is cultured for at least 5 passages; exposing the cell to the ASF virus; and allowing the ASF virus to replicate in the cell; thereby generating progeny of the ASF virus.

Provided herein are polypeptides including an amino acid sequence having at least 70% sequence identity with an Isthmin 1 (ISM1) protein or a GRP78-activating fragment thereof, as well as expressible nucleic acids encoding said polypeptides. Uses of such agents, as well as methods for inducing apoptosis in alveolar macrophages and / or for treating, ameliorating, or preventing inflammation or lung disease such as chronic obstructive pulmonary disease (COPD), emphysema, asthma, acute lung injury (ALI), lung fibrosis, and / or acute respiratory distress syndrome.

The invention discloses an active oxygen (ROS) response type targeted liposome double-drug co-delivery system for treating pulmonary fibrosis as well as a preparation method and application thereof, and belongs to the technical field of biological medicine and nano-drug delivery. Structural phospholipid, charged phospholipid, cholesterol and a polyethylene glycol-phospholipid derivative containing a thioketal bond and cRGD peptide are used as membrane materials, GC-1 is embedded into a phospholipid bilayer through a membrane hydration-extrusion method, salvianolic acid B is encapsulated in the liposome, and the liposome with negative electricity on the surface is prepared. Negative charges on the surface of the liposome are beneficial to penetrating an airway mucus barrier and reducing alveolar macrophage removal, the modified cRGD enables the liposome to be enriched in a fibrosis focus, and the thioketal bond fractured liposome rapidly disintegrates and releases drugs in a high ROS environment in a focus area. The synergistic treatment that GC-1 promotes alveolar epithelium type II cells to be redifferentiated into type I cells and salvianolic acid B removes ROS is achieved, and therefore the pulmonary fibrosis process is efficiently reversed.

The application discloses application of CD244 in a gene editing target point against African swine fever. The application provides application of a substance capable of inhibiting CD244 expression in preparation of a product for treating and / or preventing African swine fever virus infection. Inhibition of expression of the CD244 gene in porcine primary alveolar macrophage (PAM) can significantly interfere with ASFV replication, and overexpression of CD244 can significantly promote ASFV replication in an iPAM cell line. The application provides new materials for research and development of anti-ASFV infection drugs and pig disease-resistant breeding.

The invention belongs to the technical field of biological medicines, and particularly relates to acacetin-containing lipid nanoparticles for a pulmonary inhalation type mRNA vaccine as well as a preparation method and application of the acacetin-containing lipid nanoparticles. The lipid nano-particle takes acacetin as a functional fifth component, is jointly composed of ionized lipid, neutral auxiliary lipid, cholesterol and polyethylene glycol lipid, and can effectively wrap mRNA (messenger Ribonucleic Acid) of an encoding antigen. According to the preparation method, high-efficiency compounding of lipid and mRNA is realized through a microfluidic technology, the particle size of the obtained particles is adaptive to lung targeting, alveolar macrophage removal can be reduced, mRNA is protected from peroxidation damage, and vaccine response is enhanced through the immunomodulatory effect of acacetin. The system can be prepared into a lung inhalation type mRNA vaccine, is used for preventing and controlling respiratory tract infectious diseases, has high-efficiency delivery, strong immunization and good safety, and provides a new scheme for construction of a lung immune barrier.

This application relates to the field of biomedical technology, specifically disclosing a siRNA lipid nanoparticle delivery system for treating lung infections, its preparation method, and its application. This application utilizes M2 macrophage-targeting lipid nanoparticles (LNPs) as carriers, delivering WTAP-targeting siRNA to alveolar macrophages via intratracheal instillation. This achieves specific intervention in the m6A methylation modification of alveolar macrophages, thereby actively enhancing the phagocytic clearance, inflammation regulation, and bactericidal functions of AMs, ultimately improving the host's defense against lung bacterial infections (especially drug-resistant bacterial infections).

The invention discloses application of MGARP as a target spot in screening or preparing a medicine for treating silicosis. Expression of MGARP in a silicosis model is up-regulated, the effect of targeted inhibition of MGARP expression in treatment of silicosis fibrosis is verified through an in-vivo and in-vitro experimental system, specific siRNA is used for knocking down MGARP in alveolar macrophages, cell aging can be remarkably inhibited, and mitochondrial dynamic imbalance is improved; through a conditioned medium co-culture system, knock-down of MGARP can significantly inhibit fibroblast activation; knock-down of Atf3 can inhibit expression of MGARP and also improve mitochondrial damage, and the regulation effect of an ATF3 / MGARP signal axis on silicosis is prompted. According to the invention, MGARP expression is inhibited in a targeted manner, mitochondrial dysfunction is improved, and a cell aging process is inhibited, so that the activation effect of aging-related secretory phenotypes on fibroblasts is blocked, and finally pathological changes of pulmonary fibrosis are relieved.

The application discloses a medicine containing a small-molecule compound with a 2-aromatic benzoyl benzazepine structure and an application thereof. The small-molecule compound with the 2-aromatic benzoyl benzazepine structure and a pharmaceutically acceptable salt or co-crystal, deuterated compound, solvate or enantiomer thereof can be used for preparing a medicine for preventing and / or treating an inflammatory lung disease or for preparing a medicine for inhibiting alveolar macrophages from producing inflammatory factors; the medicine is a medicine for preventing and / or treating an inflammatory lung disease and contains the small-molecule compound with the 2-aromatic benzoyl benzazepine structure. The compound provided by the application can provide a new treatment strategy for the prevention or treatment of an inflammatory lung disease and has a wide application prospect.

The application belongs to the technical field of medicine, and particularly relates to a Nauclea diderrici Kotschy and Alpiniae oxyphyllae Fructus composition for regulating macrophage polarization and application thereof. The Nauclea diderrici Kotschy and Alpiniae oxyphyllae Fructus composition is obtained by mixing Nauclea diderrici Kotschy and Alpiniae oxyphyllae Fructus, adding water, heating extraction, reducing pressure concentration and drying. The composition obtained by the application can significantly reduce pro-inflammatory factors and improve anti-inflammatory factors through bidirectional regulation of alveolar macrophage polarization, and promote lung tissue repair, thereby providing a new scheme for clinical treatment of acute lung injury.